Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Immunotherapy in hepatocellular carcinoma.

Buonaguro L, Mauriello A, Cavalluzzo B, Petrizzo A, Tagliamonte M.

Ann Hepatol. 2019 Mar - Apr;18(2):291-297. doi: 10.1016/j.aohep.2019.04.003. Epub 2019 Apr 25. Review.

2.

Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma.

Löffler MW, Mohr C, Bichmann L, Freudenmann LK, Walzer M, Schroeder CM, Trautwein N, Hilke FJ, Zinser RS, Mühlenbruch L, Kowalewski DJ, Schuster H, Sturm M, Matthes J, Riess O, Czemmel S, Nahnsen S, Königsrainer I, Thiel K, Nadalin S, Beckert S, Bösmüller H, Fend F, Velic A, Maček B, Haen SP, Buonaguro L, Kohlbacher O, Stevanović S, Königsrainer A; HEPAVAC Consortium, Rammensee HG.

Genome Med. 2019 Apr 30;11(1):28. doi: 10.1186/s13073-019-0636-8.

3.

Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients.

Petrizzo A, Tagliamonte M, Mauriello A, Costa V, Aprile M, Esposito R, Caporale A, Luciano A, Arra C, Tornesello ML, Buonaguro FM, Buonaguro L.

J Transl Med. 2018 Oct 19;16(1):286. doi: 10.1186/s12967-018-1662-9.

4.

Potentiating cancer vaccine efficacy in liver cancer.

Tagliamonte M, Petrizzo A, Mauriello A, Tornesello ML, Buonaguro FM, Buonaguro L.

Oncoimmunology. 2018 Jul 23;7(10):e1488564. doi: 10.1080/2162402X.2018.1488564. eCollection 2018.

5.

Prevalence of "unclassified" HPV genotypes among women with abnormal cytology.

Annunziata C, Stellato G, Greggi S, Sanna V, Curcio MP, Losito S, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML.

Infect Agent Cancer. 2018 Jul 24;13:26. doi: 10.1186/s13027-018-0199-0. eCollection 2018.

6.

The Role of Sensing Peptides in the Cross-talk between Microbiota and Human Cancer Cells.

Tornesello AL, Buonaguro L, Tornesello ML, Buonaguro FM.

Mini Rev Med Chem. 2018;18(18):1567-1571. doi: 10.2174/1389557518666180713112119. Review.

PMID:
30003859
7.

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I.

J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z. Review.

8.

Human Oncoviruses and p53 Tumor Suppressor Pathway Deregulation at the Origin of Human Cancers.

Tornesello ML, Annunziata C, Tornesello AL, Buonaguro L, Buonaguro FM.

Cancers (Basel). 2018 Jun 22;10(7). pii: E213. doi: 10.3390/cancers10070213. Review.

9.

Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma.

Annunziata C, Pezzuto F, Greggi S, Ionna F, Losito S, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML.

Int J Cancer. 2018 Sep 1;143(5):1153-1161. doi: 10.1002/ijc.31412. Epub 2018 Apr 17.

10.

Cellular prognostic markers in hepatitis-related hepatocellular carcinoma.

Petrizzo A, Mauriello A, Tornesello ML, Buonaguro FM, Tagliamonte M, Buonaguro L.

Infect Agent Cancer. 2018 Mar 27;13:10. doi: 10.1186/s13027-018-0183-8. eCollection 2018. Review.

11.

The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma.

Pezzuto F, Buonaguro L, Buonaguro FM, Tornesello ML.

Int J Mol Sci. 2018 Mar 28;19(4). pii: E1007. doi: 10.3390/ijms19041007. Review.

12.

Telomerase promoter mutations in human immunodeficiency virus-related conjunctiva neoplasia.

Starita N, Buonaguro L, Buonaguro FM, Tornesello ML.

J Transl Med. 2018 Mar 21;16(1):77. doi: 10.1186/s12967-018-1456-0.

13.

Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting.

Petrizzo A, Mauriello A, Luciano A, Rea D, Barbieri A, Arra C, Maiolino P, Tornesello M, Gigantino V, Botti G, Ciliberto G, Buonaguro FM, Tagliamonte M, Buonaguro L.

Oncotarget. 2017 Dec 8;9(3):3576-3589. doi: 10.18632/oncotarget.23181. eCollection 2018 Jan 9.

14.

Corrigendum to "New vaccination strategies in liver cancer" [Cytokine Growth Factor Rev. 36 (2017) 125-129].

Buonaguro L; HEPAVAC Consortium.

Cytokine Growth Factor Rev. 2019 Apr;46:66. doi: 10.1016/j.cytogfr.2017.09.001. Epub 2017 Sep 12. No abstract available.

PMID:
28918939
15.

New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology.

Tornesello AL, Buonaguro L, Tornesello ML, Buonaguro FM.

Molecules. 2017 Aug 2;22(8). pii: E1282. doi: 10.3390/molecules22081282. Review.

16.

New vaccination strategies in liver cancer.

Buonaguro L; HEPAVAC Consortium.

Cytokine Growth Factor Rev. 2017 Aug;36:125-129. doi: 10.1016/j.cytogfr.2017.06.010. Epub 2017 Jun 23. No abstract available. Erratum in: Cytokine Growth Factor Rev. 2017 Sep 12;:.

PMID:
28688773
17.

Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma.

Starita N, Di Monta G, Cerasuolo A, Marone U, Anniciello AM, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML.

Infect Agent Cancer. 2017 Jun 19;12:35. doi: 10.1186/s13027-017-0147-4. eCollection 2017.

18.

Use of adjuvants for immunotherapy.

Circelli L, Tornesello M, Buonaguro FM, Buonaguro L.

Hum Vaccin Immunother. 2017 Aug 3;13(8):1774-1777. doi: 10.1080/21645515.2017.1321725. Epub 2017 Jun 12.

19.

Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma.

Pezzuto F, Buonaguro L, Buonaguro FM, Tornesello ML.

Infect Agent Cancer. 2017 May 19;12:27. doi: 10.1186/s13027-017-0138-5. eCollection 2017. Review.

20.

Comparative analysis of HPV16 gene expression profiles in cervical and in oropharyngeal squamous cell carcinoma.

Cerasuolo A, Annunziata C, Tortora M, Starita N, Stellato G, Greggi S, Maglione MG, Ionna F, Losito S, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML.

Oncotarget. 2017 May 23;8(21):34070-34081. doi: 10.18632/oncotarget.15977.

21.

Application of the Immunoscore as prognostic tool for hepatocellular carcinoma.

Petrizzo A, Buonaguro L.

J Immunother Cancer. 2016 Nov 15;4:71. eCollection 2016.

22.

Immunological effects of a novel RNA-based adjuvant in liver cancer patients.

Circelli L, Petrizzo A, Tagliamonte M, Heidenreich R, Tornesello ML, Buonaguro FM, Buonaguro L.

Cancer Immunol Immunother. 2017 Jan;66(1):103-112. doi: 10.1007/s00262-016-1923-5. Epub 2016 Nov 10.

PMID:
27832318
23.

Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery.

Petrizzo A, Caruso FP, Tagliamonte M, Tornesello ML, Ceccarelli M, Costa V, Aprile M, Esposito R, Ciliberto G, Buonaguro FM, Buonaguro L.

Sci Rep. 2016 Jul 8;6:29258. doi: 10.1038/srep29258.

24.

Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?

Gargiulo P, Della Pepa C, Berardi S, Califano D, Scala S, Buonaguro L, Ciliberto G, Brauchli P, Pignata S.

Cancer Treat Rev. 2016 Jul;48:61-8. doi: 10.1016/j.ctrv.2016.06.008. Epub 2016 Jun 18. Review.

PMID:
27362548
25.

Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.

Pezzuto F, Izzo F, Buonaguro L, Annunziata C, Tatangelo F, Botti G, Buonaguro FM, Tornesello ML.

Oncotarget. 2016 Aug 23;7(34):54253-54262. doi: 10.18632/oncotarget.9801.

26.

Detection of human papillomavirus DNA in peri-tumor tissues and pelvic lymph nodes as potential molecular marker of micrometastasis in cervical cancer.

Tortora M, Annunziata C, Liguori G, Losito S, Botti G, Greggi S, Buonaguro L, Buonaguro FM, Tornesello ML.

Infect Agent Cancer. 2016 May 11;11:22. doi: 10.1186/s13027-016-0068-7. eCollection 2016.

27.

Cancer vaccines for hepatocellular carcinoma: future directions.

Buonaguro FM, Buonaguro L.

Immunotherapy. 2016;8(4):391-3. doi: 10.2217/imt-2015-0018. No abstract available.

PMID:
26973120
28.

Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections.

Tornesello ML, Buonaguro L, Izzo F, Buonaguro FM.

Oncotarget. 2016 May 3;7(18):25087-102. doi: 10.18632/oncotarget.7837. Review.

29.

A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice.

Tagliamonte M, Petrizzo A, Napolitano M, Luciano A, Rea D, Barbieri A, Arra C, Maiolino P, Tornesello M, Ciliberto G, Buonaguro FM, Buonaguro L.

J Transl Med. 2016 Feb 24;14:58. doi: 10.1186/s12967-016-0812-1.

30.

Combinatorial immunotherapy strategies for hepatocellular carcinoma.

Tagliamonte M, Petrizzo A, Tornesello ML, Ciliberto G, Buonaguro FM, Buonaguro L.

Curr Opin Immunol. 2016 Apr;39:103-13. doi: 10.1016/j.coi.2016.01.005. Epub 2016 Feb 4. Review.

PMID:
26851637
31.

Identification of Human Herpesvirus 8 Sequences in Conjunctiva Intraepithelial Neoplasia and Squamous Cell Carcinoma of Ugandan Patients.

Starita N, Annunziata C, Waddell KM, Buonaguro L, Buonaguro FM, Tornesello ML.

Biomed Res Int. 2015;2015:801353. doi: 10.1155/2015/801353. Epub 2015 Oct 5. Review.

32.

Functional characterization of biodegradable nanoparticles as antigen delivery system.

Petrizzo A, Conte C, Tagliamonte M, Napolitano M, Bifulco K, Carriero V, De Stradis A, Tornesello ML, Buonaguro FM, Quaglia F, Buonaguro L.

J Exp Clin Cancer Res. 2015 Oct 6;34:114. doi: 10.1186/s13046-015-0231-9.

33.

Systems Biology Approach for Cancer Vaccine Development and Evaluation.

Circelli L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L.

Vaccines (Basel). 2015 Jul 14;3(3):544-55. doi: 10.3390/vaccines3030544. Review.

34.

Developments in cancer vaccines for hepatocellular carcinoma.

Buonaguro L; HEPAVAC Consortium.

Cancer Immunol Immunother. 2016 Jan;65(1):93-9. doi: 10.1007/s00262-015-1728-y. Epub 2015 Jun 21. Review.

PMID:
26093657
35.

An overview of new biomolecular pathways in pathogen-related cancers.

Tornesello ML, Buonaguro L, Buonaguro FM.

Future Oncol. 2015;11(11):1625-39. doi: 10.2217/fon.15.87. Review.

PMID:
26043216
36.

Cellular prognostic markers in hepatocellular carcinoma.

Buonaguro L, Tagliamonte M, Petrizzo A, Damiano E, Tornesello ML, Buonaguro FM.

Future Oncol. 2015;11(11):1591-8. doi: 10.2217/fon.15.39. Review.

PMID:
26043213
37.

Foreword. Cancer biomarkers.

Buonaguro FM, Tornesello ML, Buonaguro L.

Future Oncol. 2015;11(11):1585-6. doi: 10.2217/fon.15.74. No abstract available.

38.

Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies.

Pezzuto F, Buonaguro L, Caponigro F, Ionna F, Starita N, Annunziata C, Buonaguro FM, Tornesello ML.

Oncology. 2015;89(3):125-36. doi: 10.1159/000381717. Epub 2015 May 8. Review.

PMID:
25967534
39.

Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model.

Tagliamonte M, Petrizzo A, Napolitano M, Luciano A, Arra C, Maiolino P, Izzo F, Tornesello ML, Aurisicchio L, Ciliberto G, Buonaguro FM, Buonaguro L.

Cancer Immunol Immunother. 2015 Oct;64(10):1305-14. doi: 10.1007/s00262-015-1698-0. Epub 2015 May 6.

PMID:
25944003
40.

The XIX century smallpox prevention in Naples and the risk of transmission of human blood-related pathogens.

Buonaguro FM, Tornesello ML, Buonaguro L.

J Transl Med. 2015 Jan 27;13:33. doi: 10.1186/s12967-015-0400-9.

41.

TIE2-expressing monocytes: a possible cellular diagnostic and prognostic biomarker for hepatocellular carcinoma.

Buonaguro L.

Hepatobiliary Surg Nutr. 2014 Dec;3(6):419-20. doi: 10.3978/j.issn.2304-3881.2014.07.02. No abstract available.

42.

Antigen-specific vaccines for cancer treatment.

Tagliamonte M, Petrizzo A, Tornesello ML, Buonaguro FM, Buonaguro L.

Hum Vaccin Immunother. 2014;10(11):3332-46. doi: 10.4161/21645515.2014.973317. Review.

43.

TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.

Tornesello ML, Annunziata C, Buonaguro L, Losito S, Greggi S, Buonaguro FM.

J Transl Med. 2014 Sep 16;12:255. doi: 10.1186/s12967-014-0255-5.

44.

HPV-related oropharyngeal cancers: from pathogenesis to new therapeutic approaches.

Tornesello ML, Perri F, Buonaguro L, Ionna F, Buonaguro FM, Caponigro F.

Cancer Lett. 2014 Sep 1;351(2):198-205. doi: 10.1016/j.canlet.2014.06.003. Epub 2014 Jun 24. Review.

PMID:
24971935
45.

Formation of self-assembled triple-layered rotavirus-like particles (tlRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines.

Shoja Z, Tagliamonte M, Jalilvand S, Mollaei-Kandelous Y, De Stradis A, Tornesello ML, Buonaguro FM, Buonaguro L.

J Med Virol. 2015 Jan;87(1):102-11. doi: 10.1002/jmv.23973. Epub 2014 May 5.

PMID:
24797918
46.

Systems vaccinology for cancer vaccine development.

Petrizzo A, Tagliamonte M, Tornesello M, Buonaguro FM, Buonaguro L.

Expert Rev Vaccines. 2014 Jun;13(6):711-9. doi: 10.1586/14760584.2014.913484. Epub 2014 Apr 28. Review.

PMID:
24766452
47.

Human Papillomavirus Infection and Cervical Neoplasia among Migrant Women Living in Italy.

Tornesello ML, Giorgi Rossi P, Buonaguro L, Buonaguro FM; HPV Prevalence Italian Working Group.

Front Oncol. 2014 Feb 20;4:31. doi: 10.3389/fonc.2014.00031. eCollection 2014.

48.

Prediction of individual immune responsiveness to a candidate vaccine by a systems vaccinology approach.

Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L.

J Transl Med. 2014 Jan 15;12:11. doi: 10.1186/1479-5876-12-11.

49.

Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer.

Tornesello ML, Buonaguro L, Giorgi-Rossi P, Buonaguro FM.

Biomed Res Int. 2013;2013:519619. doi: 10.1155/2013/519619. Epub 2013 Dec 9. Review.

50.

Oncolytic virus therapies.

Buonaguro FM, Tornesello ML, Izzo F, Buonaguro L.

Pharm Pat Anal. 2012 Nov;1(5):621-7. doi: 10.4155/ppa.12.65. Review.

PMID:
24236929

Supplemental Content

Loading ...
Support Center